Buffalo Business & Estate Services Ltd. Takes Position in Amgen Inc. $AMGN

Key Points

• Buffalo Business & Estate Services Ltd. bought 16,716 shares of Amgen in Q4 (≈$5.47 million), representing about 0.8% of its portfolio and making AMGN its 21st-largest holding.
• Amgen beat quarterly expectations with $5.29 EPS vs. $4.76 est and $9.87 billion revenue (up 8.6% YoY), and set FY2026 guidance of 21.600–23.000 EPS.
• The company declared a quarterly dividend of $2.52 per share (annualized $10.08, ~2.9% yield; ex-dividend May 15), and institutional investors own about 76.5% of the stock.

Buffalo Business & Estate Services Ltd. acquired a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 16,716 shares of the medical research company's stock, valued at approximately $5,471,000. Amgen accounts for approximately 0.8% of Buffalo Business & Estate Services Ltd.'s portfolio, making the stock its 21st largest holding.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company's stock worth $15,204,047,000 after purchasing an additional 165,281 shares during the last quarter. State Street Corp increased its stake in shares of Amgen by 0.6% in the second quarter. State Street Corp now owns 29,357,026 shares of the medical research company's stock valued at $8,196,775,000 after purchasing an additional 177,035 shares during the period. Capital International Investors raised its holdings in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock valued at $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors boosted its position in shares of Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock worth $5,303,578,000 after buying an additional 1,935,876 shares during the period. Finally, Capital Research Global Investors boosted its position in shares of Amgen by 2.7% during the third quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company's stock worth $1,335,168,000 after buying an additional 122,631 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

AMGN opened at $347.94 on Monday. The business has a 50 day moving average price of $363.65 and a two-hundred day moving average price of $333.18. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The company has a market capitalization of $187.56 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 3.45 and a beta of 0.47. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analysts' expectations of $9.46 billion. During the same period last year, the firm earned $5.31 EPS. The firm's revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen's payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

Several analysts recently commented on AMGN shares. UBS Group raised their target price on Amgen from $380.00 to $390.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Oppenheimer set a $400.00 price target on Amgen and gave the stock an "outperform" rating in a research report on Thursday, January 29th. Freedom Capital cut Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 12th. Leerink Partners reissued a "market perform" rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. Finally, Citigroup lifted their price objective on shares of Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Amgen presently has an average rating of "Hold" and an average target price of $354.60.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.